• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Quantitative MRI may differentiate true from pseudoprogression in glioblastoma

byDylan WolmanandAaron Maxwell, MD
October 25, 2014
in Imaging and Intervention, Neurology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Contrast-enhanced magnetic resonance (MR) imaging-derived quantitative parameters of tissue permeability, particularly the volume transfer constant (Ktrans), showed moderate sensitivity and high specificity for differentiation of post-treatment glioblastoma progression from pseudoprogression.

Evidence Rating: 3 (Average)

Study Rundown: An aggressive brain tumor with a poor prognosis, glioblastoma multiforme, is typically treated with a combination of surgical resection, chemotherapy, and external beam radiation. Despite multimodal therapy, these tumors frequently recur or progress and must be carefully followed with diagnostic imaging to guide decisions regarding their course of management. Contrast-enhanced MR imaging is currently the standard of care for tumor surveillance, but its performance is limited by post-treatment changes to the tumor bed. Specifically, increased MR contrast enhancement may be due either to true tumor progression or to benign, treatment-related inflammation, a phenomenon termed pseudoprogression. Features previously suggested to indicate true progression include a reduced apparent diffusion coefficient, increased cerebral blood volume, and a subependymal enhancement pattern, but none of these findings alone is sufficiently sensitive or specific to confidently register a diagnosis.

The current study sought to expand upon the available techniques used to identify true progression by utilizing calculated pharmacokinetic parameters of tissue permeability derived from contrast-enhanced MR-images. Among patients with treated glioblastoma, one pharmacokinetic value, the volume transfer coefficient (Ktrans), was found to be highly specific and moderately sensitive for true progression when increased. This finding was theorized to represent the increased neoplastic vascular burden or increased blood-brain permeability in the tumor bed among patients with progression of their disease. The study was limited by a small sample size and the lack of a comparison to standard imaging modalities used for the evaluation of tumor progression. Further studies incorporating traditional MR and diffusion-weighted imaging are warranted to examine the cumulative predictive effect.

Click to read the study in Radiology

Relevant reading: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

In-Depth [prospective cohort]: Thirty-three patients with pathology-proven glioblastoma multiforme and new enhancing lesions within the tumor bed following surgical resection, external beam radiation, and temozolomide chemotherapy were examined using contrast-enhanced MRI with quantitative perfusion analysis. Using this technique, pharmacokinetic parameters such as Ktrans (volume transfer constant), ve (extravascular extracellular space) and vp (plasma blood volume per unit volume of tissue) were calculated for each patient. The presence or absence of true disease progression was determined by the Response Assessment in Neuro-Oncology (RANO) criteria, which specify a set of contrast-enhanced imaging findings that define true progression and pseudoprogression 12 weeks following completion of glioblastoma treatment. Quantitative MR imaging parameters were then compared to the RANO reference standard to determine the diagnostic performance of quantitative MR imaging in the diagnosis of true progression. Mean Ktrans was significantly elevated in the 17 patients exhibiting true progression versus the psuedoprogression group (P = 0.004), and mean ve was also significantly elevated in the true progression group (P = 0.034). Mean vp did not differ between the two groups (P > 0.05). Of these values, only an elevation of mean Ktrans beyond a threshold value of 0.347 min-1 was strongly predictive of tumor progression, with a sensitivity of 59% and a specificity of 94%.

RELATED REPORTS

#VisualAbstract: Magnetic resonance imaging-targeted biopsy noninferior to standard biopsy for prostate cancer screening

Low-Field, portable MRI a feasible neuroimaging alternative to traditional MRI for ICU patients

Intracranial atherosclerosis on 7T MRI and cognitive functioning – the SMART-MR study

More from this author: MR lymphangiography useful for evaluation of central lymphatic pathology, MRI may predict progression to early dementia in healthy elderly adults, Preoperative MRI improves surgical outcomes in robotic prostatectomy.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: glioblastoma multiformemri
Previous Post

Shortened tuberculosis treatment regimen inferior to standard

Next Post

STIs and recreational drug use prevalent among swingers

RelatedReports

#VisualAbstract: Prevalence of toxigenic and non-toxigenic asymptomatic Clostridioides difficile colonization in pediatric populations
StudyGraphics

#VisualAbstract: Magnetic resonance imaging-targeted biopsy noninferior to standard biopsy for prostate cancer screening

August 12, 2021
The EXTEND trial: neurological deficits decreased with thrombolysis up to 9 hours after stroke onset
Imaging and Intervention

Low-Field, portable MRI a feasible neuroimaging alternative to traditional MRI for ICU patients

September 25, 2020
Cardiology

Intracranial atherosclerosis on 7T MRI and cognitive functioning – the SMART-MR study

July 22, 2020
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Imaging and Intervention

MRI-targeted biopsies alone may underestimate grade of prostate cancer 

March 19, 2020
Next Post
STIs and recreational drug use prevalent among swingers

STIs and recreational drug use prevalent among swingers

Trials in the German Democratic Republic suggested to be ethically ambiguous

Oxaliplatin non-inferior to cisplatin for gastric cancer treatment

Oxaliplatin non-inferior to cisplatin for gastric cancer treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Sleep
  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.